Grand Brilliance Group Holdings Limited Overview
Grand Brilliance Group is a founder-controlled Hong Kong medical device distributor and "one-stop medical device solutions provider" with more than two decades of local market experience. It sources devices, consumables and instruments from roughly fifty overseas and regional manufacturers — principally in Mainland China, the United States, Germany and France — and sells them to Hong Kong hospitals, clinics and other healthcare buyers, wrapping the products with procurement advice, installation, after-sales maintenance, technical training, rental and quality-assurance services. Revenue crossed HK$100 million for the first time in FY2026 (HK$100.7 million), driven by tender wins for equipment supply to existing-hospital expansions under the HKSAR Government's First Hospital Development Plan. The company is debt-free, holds HK$53 million of cash against a market capitalisation of about HK$135 million, and is attempting to build an own-brand autonomous mobile robot (AMR) and medical-device capability to address Hong Kong's healthcare manpower shortage. Scale is very small, customer concentration is rising, and receivables quality deteriorated sharply at FY2026 year end.
The company's own description (latest annual results, FY2026)
In its FY2026 results announcement (26 June 2026), the company describes itself as an established medical device distributor and one-stop medical device solutions provider with over 20 years of experience in the Hong Kong medical device market. Its principal activities are described as the supply of medical devices and the provision of medical device solutions, comprising market trend analysis, medical device sourcing, after-sales services, technical support and training services, medical device rental services and quality assurance (Note 1 and Note 4, FY2026 results). Management states that during FY2026 it continued to implement strategies to consolidate its position as a major medical device distributor in Hong Kong, that it has established a subsidiary to facilitate future development of own-brand medical devices, and that growth was achieved through a diversified product portfolio and enhanced R&D capability.
Business model and revenue model
| Revenue model component | Description | FY2026 revenue (HKD K) | Share of FY2026 revenue (%) |
|---|---|---|---|
| Product sales — medical consumables | Single-use and recurring-purchase consumables; recognised at a point in time on delivery and acceptance | 61,902 | 61.5 |
| Product sales — medical equipment | Capital equipment, frequently via public tenders; where installation is required, revenue is recognised on customer acceptance after installation | 34,248 | 34.0 |
| Product sales — medical instruments | Reusable instruments | 1,540 | 1.5 |
| Services — maintenance | Maintenance service contracts recognised over time | 2,867 | 2.8 |
| Rental — medical device leasing | Operating-lease rental income on medical devices | 156 | 0.2 |
| Total | — | 100,713 | 100.0 |
The business is overwhelmingly a product-resale model with a thin but growing service layer:
Source: FY2026 results announcement, Note 5. Percentages analyst-derived.
There is no subscription or licensing revenue. Recurring revenue is best approximated by consumables (repeat purchasing by installed hospital/clinic accounts) plus maintenance contracts — together about 64% of FY2026 revenue. Equipment revenue is lumpier and tender-driven.
Value-chain position
The FY2023 ESG report describes the group as a bridge between overseas medical device suppliers and customers, managing pre-sale and post-sale matters, relaying product updates from manufacturers to users and channelling user feedback back to manufacturers. The value chain is: manufacturer → Grand Brilliance (registration, import, warehousing, QC inspection, sales, installation, maintenance, recall management) → hospitals, clinics and others. Quality controls disclosed include sourcing only from approved suppliers, inbound QC inspection of all products, sterilisation certificates for single-use devices, a product traceability/labelling system supporting recalls, a typical one-year product warranty to customers, and product liability insurance (FY2023 ESG report, B6).
Customer types and end-markets
Public hospitals and public-sector tenders: FY2025 and FY2026 revenue growth was explicitly attributed to winning tenders to supply medical equipment for expansions of existing hospitals under the HKSAR Government's First Hospital Development Plan (FY2025 and FY2026 results MD&A). The group also provides bank-issued performance bonds for certain tender contracts (HK$1.154 million outstanding at 31 March 2026).
Private hospitals and clinics: Not separately quantified.
Retail customers: The company redesigned its website to add an e-commerce platform for retail customers (FY2024 results, business-progress table).
Concentration: Two customers each exceeded 10% of revenue in FY2026: Customer A HK$15.689 million (15.6%) and Customer B HK$10.340 million (10.3%); in FY2025 Customer A contributed HK$18.608 million (19.7%) and Customer B HK$9.743 million (10.3%). In FY2023, no customer exceeded 10%; the top five customers contributed 32.9% and the largest 7.3% (FY2023 AR). Customer identities are not disclosed.
Independent characterisation
Grand Brilliance is a micro-cap, owner-managed distribution business whose economics resemble a specialist trading house: high gross margins for a distributor (46–52%) reflecting niche product agency rights and value-added services, but a heavy fixed cost base (administrative expenses equal to roughly 38% of revenue) that compresses operating margin to 6–10%. Growth since FY2024 has been driven by public-hospital capital equipment tenders, which carry lower margins than consumables (gross margin fell from 51.5% in FY2023 to 46.1% in FY2026, attributed by management to product-mix change). The "technology" angle — AMRs and own-brand devices — remains pre-revenue and has so far produced investment write-downs offset by a bargain-purchase accounting gain. The balance sheet is conservatively financed (no bank borrowings), but working-capital intensity is very high: inventory days of roughly 175–230 and, at FY2026 year end, receivables more than 90 days old of HK$29.5 million (69% of net trade receivables).
Strategy
Stated strategic themes (paraphrased from FY2025 and FY2026 MD&A and chairman's statements)
-
Consolidate position as a major Hong Kong medical device distributor.
-
Diversify the product portfolio to drive growth.
-
Strengthen R&D capability, including establishing a subsidiary to develop own-brand medical devices.
-
Enhance customer service to strengthen the one-stop solutions offering.
-
Automation to address healthcare manpower shortages, chiefly via AMR solutions.
-
Seek suitable investment opportunities to diversify the business and improve shareholder returns.
-
Structural tailwinds cited: an ageing population and rising health awareness in Hong Kong.
Original IPO strategy vs. execution (FY2024 results, business-progress table)
| Prospectus objective | Reported progress to 31 Mar 2024 |
|---|---|
| Penetrate market and increase share | Participation in Hospital Authority Convention, Hong Kong International Medical and Healthcare Fair, paediatric society scientific meetings; e-commerce website; showroom samples |
| Expand workforce | Recruited 7 product representatives, 2 engineers, 1 warehouse staff, 2 R&D staff, 1 admin, 2 marketing, 1 accountant |
| Selectively pursue strategic acquisitions | "Carefully identifying potential targets" — no acquisition of a revenue-generating business completed |
| Enhance R&D and product development | Recruited two software engineers; researching healthcare automation solutions |
| Upgrade IT systems | Implemented ERP with an independent consultant |
| Expand warehouse, build showroom, upgrade office | Showroom built; warehouse racking installed |
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Control of AMR JV | 6 Feb 2025 | Techmetics Sonne stake raised to 60% for US$100; aim to expand healthcare AMR footprint and develop group-branded AMR solutions | Subsidiary; no revenue contribution in FY2025 (loss HK$158,000 post-acquisition) |
| Own-brand device subsidiary | FY2025–FY2026 | Subsidiary established to drive future own-brand device development | No revenue disclosed |
| Public hospital tender programme | FY2025–FY2026 | Tender wins for equipment supply to existing hospital expansions under the First Hospital Development Plan | Main growth driver |
| Macau expansion | FY2024 onward | Non-wholly-owned subsidiary | Revenue undisclosed |
| R&D funding | FY2024–FY2026 | ITF Research Talent Hub (HK$241k FY2026), Cash Rebate Scheme for R&D investment (HK$394k FY2026), Enterprise Support Scheme (HK$21k FY2026) | Declining grant income |
| Treasury share / buyback mandates | AGM 11 Sep 2026 | General mandates to issue new shares, sell/transfer treasury shares and repurchase shares | Mandate only; no buyback executed in FY2026 |
Sustainability/ESG commitments
Targets set against an FY2022 baseline to maintain or reduce intensity through FY2030: GHG intensity (0.74 tCO2e per HK$ million revenue), non-hazardous waste intensity (11.86 kg per HK$ million), energy intensity (2,056.04 kWh per HK$ million), and total water consumption (FY2023 ESG report).
Cost programmes and medium-term financial targets
No cost-reduction programme with quantified targets, and no medium-term financial targets or guidance, have been published.
Products & Services
Disclosure limitation. The annual results announcements and the FY2023 Annual Report reviewed do not list individual product brands, models, agency agreements or prices. The catalogue below is organised at the most granular level the company discloses.
Medical consumables
Description: Recurring-use and single-use medical consumables supplied to hospitals and clinics. The company's QC procedures specifically reference single-use medical devices requiring supplier sterilisation certificates (FY2023 ESG report).
Target customers: Public and private hospitals, clinics; some retail sales via the e-commerce platform.
Pricing model: Per-unit product sales; credit terms of 0–30 days to customers (FY2026 results, Note 12).
Inventory: Consumables inventory was HK$16.340 million at 31 March 2023 (FY2023 AR, Note 21); later year splits not captured.
Named flagship offerings: Not publicly disclosed.
Medical equipment
Description: Capital medical equipment, including equipment requiring installation (revenue recognised upon customer acceptance post-installation).
Key driver: Tender wins for equipment supply to existing-hospital expansion projects under the First Hospital Development Plan (FY2025 and FY2026 MD&A).
Pricing model: Tender-based contract pricing; performance bonds provided via banks for certain tender contracts (HK$1.154 million at 31 March 2026, with most contracts expected to complete by FY2027).
Named flagship offerings: Not publicly disclosed.
Medical instruments
Description: Reusable medical instruments. Revenue has declined every year since FY2022 (HK$2.445 million in FY2022).
Named flagship offerings: Not publicly disclosed.
Maintenance and after-sales services
Description: Maintenance service contracts recognised over the contract period, delivered through dedicated subsidiary 鴻日工程服務有限公司. The group designates staff and engineers to inspect medical equipment regularly and maintains repair-process records (FY2023 ESG report).
Growth: +23.7% in FY2026, the fastest-growing line, consistent with a larger installed equipment base.
Medical device rental (FY2026 revenue HK$156,000; 0.2%)
Description: Operating leases of medical devices; flat at HK$156,000 per year since FY2023.
Solutions services (embedded in product revenue)
The company markets a bundled "one-stop solution" comprising: market trend analysis; medical device sourcing; after-sales services; technical support and training; rental; and quality assurance (FY2026 results, Note 1). These are not separately priced in disclosures.
Pipeline / development-stage offerings
| Offering | Status | Vehicle | Source |
|---|---|---|---|
| Own-brand autonomous mobile robot (AMR) solutions for healthcare | In development; positioned to relieve Hong Kong healthcare manpower shortage; residual IPO proceeds (HK$0.4 million) fully used in FY2025 | Techmetics Sonne Limited (60% subsidiary since Feb 2025) | FY2025 results |
| Own-brand medical devices | Subsidiary established to facilitate future development | Unnamed subsidiary | FY2025 and FY2026 results MD&A |
| Healthcare automation solutions | Two software engineers recruited; research into medical and healthcare automation | Group R&D | FY2024 results (business progress) |
| E-commerce platform | Website redesigned with online store for retail customers | Group | FY2024 results |
| Showroom | New showroom with device samples for customer inspection prior to ordering | HQ | FY2024 results |
Financial Narrative
All figures HK$'000 unless stated; FY ends 31 March. Sources: FY2023 AR (FY2022–FY2023); FY2024, FY2025 and FY2026 audited results announcements.
Income statement: notes and sources
Notes: (1) FY2023 "other gains or losses" was reported as HK$417,000 in the FY2023 AR; the FY2024 announcement re-presented it as HK$338,000 with the HK$79,000 receivable-allowance reversal shown separately — the totals reconcile. (2) In FY2022 the HK$87,000 receivable allowance was not presented as a separate line in the FY2023 AR income statement. (3) Dividends are declared after year end as "interim dividends in lieu of a final dividend".
Analyst-derived profitability measures
Definitions: Core operating profit = gross profit − distribution & selling − administrative expenses (excludes other income, investment gains/losses, associates and the bargain purchase gain). EBITDA = profit before tax + finance costs + depreciation of PP&E and right-of-use assets (reported basis; includes other income such as interest and grants). D&A from the "profit before tax" notes.
Revenue CAGR: FY2022–FY2026 four-year CAGR ≈ 8.8%; FY2019–FY2026 seven-year CAGR ≈ 8.2% (analyst-derived from reported revenue).
Commentary — revenue and margins. Revenue has compounded at a steady high-single-digit rate with one step-change (FY2025, +15.3%) driven by hospital equipment tenders. Gross margin peaked at 51.5% in FY2023 (management cited improved transport cost control) and has since contracted 540 basis points to 46.1% as lower-margin equipment grew. The gross profit line consequently grew only 1.4% in FY2026 despite 6.6% revenue growth.
Commentary — operating leverage. Administrative expenses rose 16.0% in FY2024 (marketing activity and salary increases) and 6.9% in FY2025 (salaries), then were flat in FY2026 (HK$37.9 million). Flat opex in FY2026 is the main reason core operating margin held at 7.0%. Staff costs rose from HK$18.2 million (FY2022) to HK$24.5 million (FY2026).
Commentary — quality of earnings. Reported profit has been meaningfully supported by non-operating items: other income (interest plus government R&D and employment subsidies) contributed HK$4.2 million in FY2024 and HK$3.4 million in FY2025, versus HK$1.7 million in FY2026. The FY2025 profit also included a HK$975,000 bargain purchase gain, partly offset by a HK$1.529 million write-down of the Techmetics investment. Management attributed the FY2026 decline in profit (HK$9.2 million to HK$8.1 million) mainly to lower government grants. Bank interest income fell from HK$1.615 million to HK$940,000 in FY2026 as cash balances declined and rates eased. The FY2024 effective tax rate of 5.1% was attributed to tax planning adopted by group companies (FY2024 MD&A); unutilised tax losses of HK$7.1 million existed at 31 March 2023.
Balance sheet
Notes: Negative net debt = net cash. No goodwill is recognised on the balance sheet; goodwill of HK$663,000 arising on the 寶存 investment is embedded in the associate carrying amount (FY2023 AR Note 16). No intangible assets other than the club membership are recognised.
Commentary — balance sheet. The group has carried no bank debt since listing; the only financial liabilities are short warehouse/office leases. Equity has grown every year, and equity represented 87% of total assets at FY2026. The critical change is the composition of current assets: net trade receivables tripled from HK$13.9 million (FY2024) to HK$42.6 million (FY2026), while cash fell HK$7.1 million in FY2026. The FY2026 receivables ageing shows HK$29.533 million over 90 days (FY2025: HK$593,000) against stated credit terms of 0–30 days — consistent with slow-paying tender/project customers, but this has not been explained in the results announcement. Loss allowance was raised only modestly (HK$1.733 million vs HK$1.461 million).
Cash flow
Sources: FY2023 AR consolidated cash flow statement (FY2022–FY2023). FY2024–FY2026 operating cash flow, capex and lease repayments were not captured in the sources reviewed (the results announcements omit the cash-flow statement; the full annual reports contain them). Dividends paid FY2024–FY2026 from dividend notes; net change in cash derived from balance sheets; buybacks confirmed nil by "purchase, sale or redemption" disclosures.
Commentary — cash generation. Cash conversion is volatile and dominated by working-capital swings. FY2022 operating cash flow was negative (receivables build of HK$9.7 million); FY2023 was strongly positive. The FY2026 combination of rising profit-before-tax-ex-items, a HK$17.2 million increase in net trade receivables and a HK$7.1 million cash decline (after only HK$2.0 million of dividends) strongly suggests that FY2026 operating cash flow was weak, but the exact figure is not reported in the announcement and is not estimated here.
Ratios (analyst-derived)
Methodology: ROE = attributable profit / average attributable equity; ROA = total profit / average total assets; ROIC = core operating profit × (1 − 16.5%) / year-end invested capital (total equity + lease liabilities − cash); interest coverage = core operating profit / lease interest; CCC on year-end balances (DSO = net trade receivables / revenue × 365; DIO = inventory / cost of revenue × 365; DPO = trade payables / cost of revenue × 365). FY2021 year-end balances (equity HK$93.052 million; total assets HK$112.010 million) used for FY2022 averages.
Commentary — returns. ROE of 7–9% is modest and structurally depressed by the large cash pile (cash was 45% of equity at FY2026). ROIC on operating capital is higher but has declined from 15.6% (FY2023) to 8.8% (FY2026) as receivables swelled invested capital from HK$42 million to HK$66 million. The cash conversion cycle lengthened to 286 days in FY2026 — the inventory side improved, but DSO more than doubled from FY2024. Dividend payout has been cut from 42–59% (FY2022–FY2023) to 21–25% (FY2024–FY2026) despite higher earnings, with DPS fixed at HK$0.25 cents for three consecutive years.
Half-year trend (analyst-derived from interim headline)
Derivation: 1H FY2026 revenue approx. HK$52.5 million (+25.9%, per the 21 November 2025 interim announcement headline) implies 1H FY2025 ≈ HK$41.7 million; second halves = full-year less first half. The derived 2H FY2026 revenue was about 8.5% below 2H FY2025, indicating that growth was front-loaded and decelerated sharply in the second half. Interim profit was approx. HK$3.9 million, implying roughly HK$4.2 million in 2H FY2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Category (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical consumables (HKD K) | 53,699 | 55,061 | 54,985 | 58,646 | 61,902 |
Medical equipment (HKD K) | 14,251 | 17,476 | 22,899 | 31,657 | 34,248 |
Medical instruments (HKD K) | 2,445 | 1,807 | 1,756 | 1,672 | 1,540 |
Maintenance services (HKD K) | 1,394 | 2,201 | 2,107 | 2,317 | 2,867 |
Rental income (HKD K) | 189 | 156 | 156 | 156 | 156 |
Total revenue (HKD K) | 71,978 | 76,701 | 81,903 | 94,448 | 100,713 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCategory growth (%)
| Category growth (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Medical consumables growth (%) | 2.5 | -0.1 | 6.7 | 5.6 |
Medical equipment growth (%) | 22.6 | 31.0 | 38.2 | 8.2 |
Medical instruments growth (%) | -26.1 | -2.8 | -4.8 | -7.9 |
Maintenance services growth (%) | 57.9 | -4.3 | 10.0 | 23.7 |
Total revenue growth (%) | 6.6 | 6.8 | 15.3 | 6.6 |
Category share (%)
| Category share (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical consumables share (%) | 74.6 | 71.8 | 67.1 | 62.1 | 61.5 |
Medical equipment share (%) | 19.8 | 22.8 | 28.0 | 33.5 | 34.0 |
Medical instruments share (%) | 3.4 | 2.4 | 2.1 | 1.8 | 1.5 |
Maintenance services share (%) | 1.9 | 2.9 | 2.6 | 2.5 | 2.8 |
Rental income share (%) | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
Revenue by Segment by Recognition Timing
| Recognition timing (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Recognised over time (HKD K) | 1,394 | 2,201 | 2,107 | 2,317 | 2,867 |
Recognised at a point in time (HKD K) | 70,395 | 74,344 | 79,640 | 91,975 | 97,690 |
Group Entities
| Entity | Place of incorporation | Effective interest | Principal activity | Source |
|---|---|---|---|---|
Grand Brilliance Group Holdings Limited | Cayman Islands | Listed parent | Investment holding | FY2026 results |
A&A Brilliance Limited | BVI (4 Jul 2017) | 100% direct | Investment holding | FY2023 AR Note 32 |
鴻日醫療有限公司 | Hong Kong (15 Oct 1997) | 100% indirect | Medical device sourcing and after-sales services | FY2023 AR Note 32 |
向日國際有限公司 | Hong Kong (11 Mar 2009) | 100% indirect | Medical device sourcing and healthcare product development | FY2023 AR Note 32 |
向日科技國際有限公司 | Hong Kong (4 Jul 2016) | 100% indirect | Trademark holding | FY2023 AR Note 32 |
Sonne (UK) Limited | United Kingdom (26 Aug 2016) | 100% indirect | Trademark holding | FY2023 AR Note 32 |
Solar Service Engineering Holdings Limited | BVI (12 Mar 2019) | 100% indirect | Investment holding | FY2023 AR Note 32 |
鴻日工程服務有限公司 | Hong Kong (10 May 2019) | 100% indirect | Maintenance services | FY2023 AR Note 32 |
Macau subsidiary (name not captured) | Macau (FY2024) | Non-wholly owned (stake not disclosed in sources reviewed) | Expansion of Macau business; subject to 12% Macau complementary tax | FY2024 results MD&A; FY2025/FY2026 tax note |
Techmetics Sonne Limited (晉暉科技有限公司) | Hong Kong (19 Aug 2021) | 60% indirect since 6 Feb 2025 (previously 20% associate) | Healthcare AMR solutions, OEM sourcing, R&D | FY2025 results Note 16 |
Own-brand medical device subsidiary (name not captured) | Hong Kong (assumed; not stated) | — | Development of own-brand medical devices | FY2025/FY2026 results MD&A |
寶存有限公司 | Hong Kong (1 Aug 2016) | 16.1% associate (as at 31 Mar 2023) | Supply chain solutions | FY2023 AR Note 16 |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD K) | 71,978 | 76,701 | 81,903 | 94,448 | 100,713 |
Cost of revenue (HKD K) | -35,631 | -37,189 | -39,962 | -48,726 | -54,331 |
Gross profit (HKD K) | 36,347 | 39,512 | 41,941 | 45,722 | 46,382 |
Other income (HKD K) | 26 | 1,475 | 4,239 | 3,421 | 1,722 |
Other gains or losses (HKD K) | -326 | 338 | -910 | -648 | 703 |
Bargain purchase gain (HKD K) | 0 | 0 | 0 | 975 | 0 |
Distribution and selling expenses (HKD K) | -1,197 | -1,209 | -1,319 | -1,397 | -1,454 |
Administrative and other operating expenses (HKD K) | -29,232 | -30,470 | -35,354 | -37,785 | -37,896 |
Trade receivable loss allowance (provision)/reversal (HKD K) | 0 | 79 | -18 | 10 | -272 |
Share of associates' results (HKD K) | 0 | -196 | -263 | 18 | 74 |
Finance costs — lease interest (HKD K) | -140 | -152 | -106 | -208 | -214 |
Profit before tax (HKD K) | 5,478 | 9,377 | 8,210 | 10,108 | 9,045 |
Income tax (HKD K) | -1,430 | -1,815 | -420 | -917 | -937 |
Profit for the year (HKD K) | 4,048 | 7,562 | 7,790 | 9,191 | 8,108 |
Profit attributable to owners (HKD K) | 4,048 | 7,562 | 7,855 | 9,460 | 8,413 |
Non-controlling interests (HKD K) | 0 | 0 | -65 | -269 | -305 |
Basic and diluted EPS (HK cents) | 0.51 | 0.95 | 0.98 | 1.18 | 1.05 |
Dividend per share declared for the year (HK cents) | 0.3 | 0.4 | 0.25 | 0.25 | 0.25 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Core operating profit (HKD K) | 5,918 | 7,833 | 5,268 | 6,540 | 7,032 |
Depreciation — PP&E (HKD K) | 615 | 389 | 617 | 746 | 679 |
Depreciation — right-of-use assets (HKD K) | 3,637 | 3,977 | 3,999 | 2,889 | 1,905 |
EBITDA (HKD K) | 9,870 | 13,895 | 12,932 | 13,951 | 11,843 |
Gross margin (%) | 50.5 | 51.5 | 51.2 | 48.4 | 46.1 |
Core operating margin (%) | 8.2 | 10.2 | 6.4 | 6.9 | 7.0 |
EBITDA margin (%) | 13.7 | 18.1 | 15.8 | 14.8 | 11.8 |
Pre-tax margin (%) | 7.6 | 12.2 | 10.0 | 10.7 | 9.0 |
Net margin (%) | 5.6 | 9.9 | 9.5 | 9.7 | 8.1 |
Effective tax rate (%) | 26.1 | 19.4 | 5.1 | 9.1 | 10.4 |
Admin expenses as % of revenue (%) | 40.6 | 39.7 | 43.2 | 40.0 | 37.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD K) | 110,324 | 115,248 | 114,495 | 132,192 | 134,702 |
Non-current assets (HKD K) | 12,902 | 13,607 | 10,300 | 10,552 | 7,736 |
Current assets (HKD K) | 97,422 | 101,641 | 104,195 | 121,640 | 126,966 |
Cash and cash equivalents (HKD K) | 55,336 | 61,085 | 59,988 | 60,235 | 53,123 |
Inventories (HKD K) | 22,442 | 22,153 | 24,500 | 27,799 | 25,973 |
Trade receivables, net (HKD K) | 17,310 | 15,703 | 13,943 | 25,317 | 42,552 |
Trade and other receivables, deposits and prepayments — current (HKD K) | 19,132 | 17,630 | 18,203 | 31,615 | 46,797 |
Bank borrowings (HKD K) | 0 | 0 | 0 | 0 | 0 |
Lease liabilities — current (HKD K) | 2,400 | 3,766 | 1,429 | 1,852 | 1,624 |
Lease liabilities — non-current (HKD K) | 2,081 | 688 | 0 | 2,054 | 429 |
Total lease liabilities (HKD K) | 4,481 | 4,454 | 1,429 | 3,906 | 2,053 |
Net debt including leases (HKD K) | -50,855 | -56,631 | -58,559 | -56,329 | -51,070 |
Trade payables (HKD K) | 7,107 | 5,969 | 3,875 | 7,925 | 6,291 |
Current liabilities (HKD K) | 14,734 | 15,889 | 11,219 | 18,695 | 16,722 |
Total liabilities (HKD K) | 16,815 | 16,577 | 11,219 | 20,749 | 17,151 |
Equity attributable to owners (HKD K) | 93,509 | 98,671 | 103,326 | 110,786 | 117,199 |
Total equity (HKD K) | 93,509 | 98,671 | 103,276 | 111,443 | 117,551 |
Other assets — club membership, indefinite life (HKD K) | 2,690 | 2,690 | 2,690 | 2,690 | 2,680 |
Working capital (current assets less current liabilities) (HKD K) | 82,688 | 85,752 | 92,976 | 102,945 | 110,244 |
Cash Flow
| Metric (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (HKD K) | -3,334 | 12,658 | — | — | — |
Capital expenditure — PP&E purchases (HKD K) | -784 | -63 | — | — | — |
Free cash flow (OCF less capex) (HKD K) | -4,118 | 12,595 | — | — | — |
Lease principal repaid (HKD K) | -3,842 | -3,847 | — | — | — |
Dividends paid (HKD K) | -3,600 | -2,400 | -3,200 | -2,000 | -2,000 |
Share buybacks (HKD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash and equivalents (HKD K) | -14,876 | 5,749 | -1,097 | 247 | -7,112 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 4.3 | 7.9 | 7.8 | 8.8 | 7.4 |
ROA (%) | 3.6 | 6.7 | 6.8 | 7.5 | 6.1 |
ROIC (%) | 11.6 | 15.6 | 9.8 | 9.9 | 8.8 |
Current ratio (x) | 6.61 | 6.40 | 9.29 | 6.51 | 7.59 |
Bank debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
Lease liabilities to equity (%) | 4.8 | 4.5 | 1.4 | 3.5 | 1.7 |
Net debt to EBITDA (x) | -5.15 | -4.08 | -4.53 | -4.04 | -4.31 |
Interest coverage (x) | 42.3 | 51.5 | 49.7 | 31.4 | 32.9 |
Asset turnover (x) | 0.65 | 0.68 | 0.71 | 0.77 | 0.75 |
Days sales outstanding (days) | 87.8 | 74.7 | 62.1 | 97.8 | 154.2 |
Days inventory outstanding (days) | 229.9 | 217.4 | 223.8 | 208.2 | 174.5 |
Days payables outstanding (days) | 72.8 | 58.6 | 35.4 | 59.4 | 42.3 |
Cash conversion cycle (days) | 244.9 | 233.5 | 250.5 | 246.6 | 286.4 |
Dividend payout on declared DPS (%) | 59.3 | 42.3 | 25.5 | 21.1 | 23.8 |
Income Statement
| Period metric | 1H FY2025 | 2H FY2025 | 1H FY2026 | 2H FY2026 |
|---|---|---|---|---|
Revenue (HKD Mn) | 41.7 | 52.7 | 52.5 | 48.2 |
Region revenue (HKD K)
| Region revenue (HKD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong and other (as reported, total) (HKD K) | 71,978 | 76,701 | 81,903 | 94,448 | 100,713 |
Geographic Revenue
| Supplier country (number of suppliers) | FY2022 | FY2023 |
|---|---|---|
Mainland China (suppliers) | 19 | 22 |
United States (suppliers) | 15 | 15 |
Germany (suppliers) | 5 | 5 |
France (suppliers) | 4 | 4 |
Malaysia (suppliers) | 3 | 3 |
Hong Kong (suppliers) | 0 | 3 |
Singapore (suppliers) | 0 | 1 |
Total suppliers (suppliers) | 46 | 53 |
Valuation Metric Details
| Valuation metric | Value | Basis |
|---|---|---|
Share price | HK$0.169 | etnet last price |
Shares outstanding | 800,000,000 | FY2026 results |
Market capitalisation | HK$135.2m | Calculated |
Enterprise value | HK$84.5m | Market cap − cash HK$53.1m + leases HK$2.1m + NCI HK$0.35m |
Trailing P/E | 16.1x | FY2026 EPS 1.05 cents |
EV/EBITDA | 7.1x | FY2026 EBITDA HK$11.8m (analyst-derived) |
EV/Sales | 0.84x | FY2026 revenue |
P/B | 1.15x | Equity attributable HK$117.2m |
Dividend yield | 1.5% | DPS 0.25 cents |
Net cash as % of market cap | 38% | — |
Dividend metric
| Dividend metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
DPS declared for the year (HK cents) | 0.3 | 0.4 | 0.25 | 0.25 | 0.25 |
Total dividend declared for the year (HKD K) | 2,400 | 3,200 | 2000 | 2000 | 2000 |
Dividends paid in the year (HKD K) | 3,600 | 2,400 | 3,200 | 2000 | 2000 |
Analyst Conclusions
Management guidance
No quantitative guidance. Management states continued optimism on Hong Kong healthcare given population ageing, health awareness and automation demand, and that it is seeking investment opportunities to diversify (FY2026 MD&A).
Consensus
No consensus estimates exist.
Bull case
-
Structural tender pipeline: equipment revenue more than doubled from HK$14.3m (FY2022) to HK$34.2m (FY2026) on hospital expansion tenders; if public capital works continue, the installed base also lifts recurring maintenance (+23.7% in FY2026) and consumables pull-through.
-
Deep value with optionality: at ~7x EV/EBITDA and with net cash equal to ~38% of market cap, the market ascribes modest value to a consistently profitable business, before any own-brand or AMR upside.
-
Capital-return catalyst: a payout ratio of only ~24% and a fresh repurchase mandate give scope for higher dividends or buybacks from HK$53m of idle cash.
Bear case
-
Receivables quality: HK$29.5m over 90 days (69% of net trade receivables) against 0–30-day terms; an impairment of even one-third would erase more than a year's profit.
-
Decelerating growth and margin compression: derived 2H FY2026 revenue fell ~8.5% YoY; gross margin has fallen four years running; grant and interest income are fading.
-
Governance and capital-allocation risk: controlling-shareholder dominance (combined roles, spouse on audit committee, related-party lease and JV co-investment), recurrent INED departures, and a track record of small, value-destructive technology investments.
Key catalysts and monitorables (next 12 months)
1H FY2027 interim results: (six months to 30 Sep 2026; expected around November 2026): watch revenue against the strong 1H FY2026 comparative (~HK$52.5m), gross margin, and especially collection of the >90-day receivables.
FY2026 Annual Report cash-flow statement: (published 21 Jul 2026): confirm operating cash flow and capex.
Board composition: explain the three Company Information Sheet updates (31 Aug, 8 Sep, 18 Sep 2026).
Hospital Development Plan tender awards: and HKSAR budget signals on hospital capital works.
Any first revenue: from Techmetics Sonne / own-brand AMR or devices; Macau revenue disclosure.
Use of repurchase mandate: or any change in dividend level.
M&A: given repeated statements about seeking investment opportunities.
Analyst verdict
Grand Brilliance Group is a small, durable, conservatively financed Hong Kong distribution business that has executed better on the top line than its GEM-micro-cap status might suggest: revenue has compounded at close to 9% a year since FY2022 to cross HK$100 million in FY2026, it has never needed bank debt, and it has paid a dividend every year. The engine of that growth, however, has changed character. Public-hospital equipment tenders now represent a third of sales, bringing lower gross margins, lumpier timing and — on the evidence of the FY2026 balance sheet — much slower cash collection.
Against this, valuation is undemanding. Roughly 38% of the market capitalisation is covered by net cash, the stock trades near 1.15x book and about 7x EV/EBITDA, and the payout ratio leaves ample room for higher distributions. Yet capital-allocation discipline has been mixed: the AMR diversification has so far yielded write-downs offset by an accounting gain, related-party features recur, and governance relies heavily on a single founder who holds both leadership roles and 71% of the shares.
On balance, the investment case is neutral with a cautious bias until the receivables position is resolved. Confirmation that the overdue balances were collected after year end — ideally visible in the 1H FY2027 interim results — together with stabilisation of gross margin near 46% and a more generous use of surplus cash would move the assessment towards positive. Conversely, an impairment charge, further INED turnover or another non-core investment would reinforce the bear case. Liquidity constraints typical of GEM stocks argue for position sizing appropriate to a micro-cap.
Prepared from public HKEX filings and identified aggregators as of 10 October 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age (as stated in FY2023 AR, June 2023) | Background and education | Source |
|---|---|---|---|---|---|
Ms. Wong Bik Kwan Bikie (黃碧君) | Chairman, CEO, executive director, compliance officer; remuneration committee member | Director 5 Jul 2017; ED 18 Sep 2017; Chair & CEO 1 Mar 2018 | 54 | Founded the group in Nov 1997; over 29 years in Hong Kong medical device market (as of 2023); Diploma in General Nursing (1990), MBA, University of South Australia (1999); awards incl. Greater Bay Area Outstanding Women Entrepreneur Award (2018); vice-chair of Yan Oi Tong and of a GBA Hong Kong women entrepreneurs association | FY2023 AR |
Dr. Miu Yin Shun Andrew (苗延舜) | Non-executive director; audit committee member | 18 Sep 2017 | 56 | MBChB, Chinese University of Hong Kong (1990); FRCS Edinburgh (1995), orthopaedics fellowships; MSc Sports Medicine & Health Science, CUHK (2015); orthopaedic specialist since 2011; spouse of Ms. Wong; advises on medical device technical information | FY2023 AR |
Mr. Chiu Man Wai (趙文煒) | Non-executive director; nomination committee member | 18 Sep 2017 | 54 | BA Mathematics (1990) and MSc Mathematical Modelling & Numerical Analysis (1991), University of Oxford; research roles incl. head of research at BNP Paribas Equities Hong Kong (1996–2004); director of financial investment and insurance advisory companies; advises on investor relations | FY2023 AR |
Mr. Ng Leung Sing SBS, JP (吳亮星) | INED; nomination committee chair | 1 Mar 2018 | 73 | Director, BOC-Group Trustee (HK) since 2009; former director of HK Mortgage Corporation (2014–2018); INED of SmarTone (315) and Nine Dragons Paper (2689); former HK deputy to National People's Congress; former Legislative Council member; law diploma, University of East Asia, Macau (1987) | FY2023 AR |
Mr. Chow Ming Po Aaron (周明寶) | INED; remuneration committee chair; audit and nomination committee member | 21 Jun 2021 | 50 | Practising solicitor; LLB and PCLL, University of Hong Kong (1995/1996); co-founder and partner of a Hong Kong law firm since 2006 | FY2023 AR |
Mr. 趙㠶華 (English name not captured) | INED; audit committee chair; remuneration committee member | 1 Jun 2025 | Not captured | Appointed to restore accounting-expertise INED requirement under GEM Rule 5.05(2); biography not captured in sources reviewed | FY2025 and FY2026 results |
Executive Leadership Team
| Name | Title | Joined | Age (June 2023) | Background |
|---|---|---|---|---|
何海燕 | General Manager | Mar 2020 (GM from 2021) | 42 | Bachelor of Commerce (Marketing & Advertising), Curtin University; product manager at Synapse Therapeutics (2011–2018) |
張創智 | Financial Controller | 12 Aug 2019 | 45 | BBA, CUHK (1999); FCPA (HKICPA), FCCA; oversees accounting, finance, company secretarial and internal control |
李春成 | Business Development Manager | Jan 1998 | 53 | Over 23 years in medical equipment; former electrical engineer |
劉偉民 | Marketing, Projects & Service Engineering Manager | Feb 2015 | 36 | BEng Medical Engineering, HKU (2008); MSc Biomedical Engineering, CUHK (2009) |
李嘉文 | Company Secretary (external provider) | — | — | Member of HKCGI and CGI; over 17 years' company secretarial experience |
Directors' Remuneration
| Director | Fees | Salaries & benefits | Discretionary bonus | Pension | Total |
|---|---|---|---|---|---|
Ms. Wong Bik Kwan Bikie | 0 | 2,992 | 1,211 | 22 | 4,225 |
Dr. Miu Yin Shun Andrew | 120 | 0 | 0 | 0 | 120 |
Mr. Chiu Man Wai | 120 | 0 | 0 | 0 | 120 |
Mr. Ng Leung Sing | 120 | 0 | 0 | 0 | 120 |
Mr. Wong Lung Wo James (former) | 120 | 0 | 0 | 0 | 120 |
Mr. Chow Ming Po Aaron | 120 | 0 | 0 | 0 | 120 |
Total | 600 | 2,992 | 1,211 | 22 | 4,825 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
17 Sep 2021 | Chan Ping Keung retired as INED | Did not seek re-election, citing work adjustment |
21 Jun 2021 | Chow Ming Po Aaron appointed INED | — |
18 Sep 2023 | Wong Lung Wo James resigned; Mui Wai Sum appointed INED and audit chair | — |
14 Mar 2025 | Mui Wai Sum resigned (other commitments) | Triggered non-compliance with GEM Rules 5.05(1), 5.05(2), 5.28 and 5.34 |
1 Jun 2025 | 趙㠶華 appointed INED, audit chair | Compliance restored |
Aug–Sep 2026 | Company Information Sheets (Form G) updated 31 Aug, 8 Sep and 18 Sep 2026 | may reflect post-AGM or administrative changes — monitor |
Major Shareholders
| Holder | Shares | Stake (%) | Nature | Source / date |
|---|---|---|---|---|
B&A Success Limited (wholly owned by Ms. Wong) | 568,028,001 | 71.0 | Beneficial owner | FY2023 AR (31 Mar 2023) |
Ms. Wong — share options | 7,980,000 underlying | 1.0 | Options at HK$0.12, expiring 17 Apr 2024 (post-expiry status not captured) | FY2023 AR |
Mr. Chiu Man Wai (via Infinite Crystal Limited) | 9,620,000 | 1.20 | Controlled corporation | FY2023 AR |
Mr. Chow Ming Po Aaron | 7,810,000 | 0.98 | Beneficial owner | FY2023 AR |
Public / other | ~214.5 million | ~26.8 | — | Analyst-derived |
Competitive Landscape
Key Competitors
| # | Competitor | Type | Overlap with GBG |
|---|---|---|---|
| 1 | Medtronic (Hong Kong subsidiary) | Multinational direct sales | Hospital equipment and consumables tenders |
| 2 | Johnson & Johnson MedTech | Multinational direct sales | Surgical consumables and instruments |
| 3 | B. Braun | Multinational direct sales | Consumables, infusion, instruments |
| 4 | BD (Becton, Dickinson) | Multinational direct sales | Consumables |
| 5 | Siemens Healthineers | Multinational direct sales | Capital equipment |
| 6 | GE HealthCare | Multinational direct sales | Capital equipment |
| 7 | Philips | Multinational direct sales | Capital equipment, monitoring |
| 8 | Olympus | Multinational direct sales | Endoscopy equipment and instruments |
| 9 | DKSH | Regional market-expansion distributor | Third-party distribution of healthcare products |
| 10 | Zuellig Pharma | Regional healthcare distributor | Healthcare distribution logistics |
| 11 | Private Hong Kong distributors (numerous; unnamed) | Local SMEs | Agency-based distribution of niche brands |
Competitor Detail
| Metric (latest FY) | Grand Brilliance (FY2026) |
|---|---|
Revenue | HK$100.7m |
Revenue growth | 6.6% |
Gross margin | 46.1% |
Operating margin (core) | 7.0% |
R&D intensity | 4.6% |



